Skip to main content
Omkar Pharmachem Ltd. logo

Omkar Pharmachem Ltd. — Investor Relations & Filings

Ticker · 532167 ISIN · INE501C01015 BSE.NS Manufacturing
Open in API
Filings indexed 7 across all filing types
Latest filing 2026-06-01 Report Publication Anno…
Country IN India
Listing BSE.NS 532167

About Omkar Pharmachem Ltd.

https://omkarpharmachem.co.in/

Omkar Pharmachem Ltd. is an enterprise primarily engaged in the manufacturing, trading, and distribution of active pharmaceutical ingredients (APIs) and chemical intermediates. The company focuses on providing a diverse range of chemical compounds and specialty chemicals tailored for healthcare and industrial applications. Its core operations involve the sourcing and supply of chemical formulations and raw materials used in various medicinal processes. Omkar Pharmachem Ltd. emphasizes maintaining a robust supply chain to serve its client base, ensuring the availability of essential chemical components for development and production. The portfolio includes a variety of organic and inorganic chemicals, catering to the specific requirements of laboratories and manufacturing units. The company maintains a focus on quality control and technical standards in the distribution of its chemical products.

Recent filings

Filing Released Lang Actions
Dear Sir, Please find attached copy of News Paper Publication in which Audited Financial Results for the Quarter and Year ended 31st March 2026 are published, one in English and one in ....
Report Publication Announcement Classification · 82% confidence The document is a formal BSE filing by Omkar Pharmachem Ltd. notifying the stock exchange that its audited financial results for the quarter and year ended March 31, 2026 have been published via newspaper advertisement, with a copy of that advertisement enclosed. The company is not providing a full report or detailed financial statements itself but merely announcing and attaching proof of publication of results. This fits the definition of a Report Publication Announcement (RPA).
2026-06-01 English
Dear Sir/Ma''am, Please find Financial Results for the quarter and year ended 31.03.2026
Interim / Quarterly Report Classification · 85% confidence The document is an audited financial results submission under Regulation 33 of SEBI LODR for the quarter and financial year ended March 31, 2026. It includes actual standalone financial statements, the auditor’s report, balance sheet, cash flows, and notes. It is not a full annual report (10-K) but rather a periodical financial disclosure for a quarter/year-end. Therefore, it fits the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-30 English
Dear Sir, Please find Outcome of the Board Meeting held on 30 May, 2026 of Omkar Pharmachem Limited
Audit Report / Information Classification · 92% confidence The document is the official board meeting outcome under SEBI LODR Regulation 33, comprising the Independent Auditor’s Report and the audited standalone financial results (tables of income, assets & liabilities) for quarter and year ended March 31, 2026. It is not a full annual report but the standalone audit report with financial results disclosure. This matches the definition of Audit Report / Information (AR). FY 2026
2026-05-30 English
Dear Sir/Ma''am, Please find Annual Secretarial Compliance report for the year ended 31.03.2026 of Omkar Pharmachem Limited.
Audit Report / Information Classification · 95% confidence The document is titled “Annual Secretarial Compliance Report” issued pursuant to SEBI LODR Regulation 24A (2) for the year ended 31 March 2026. It is a standalone compliance/audit report prepared by a Practicing Company Secretary and filed with the stock exchange. It is not a full Annual Report, Earnings Release, or proxy solicitation, nor is it merely an announcement. This matches the definition of a standalone audit/compliance report. Therefore, it is classified as Audit Report / Information (AR). FY 2026
2026-05-27 English
Omkar Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Omkar Pharmachem Ltd. has ....
Regulatory Filings Classification · 85% confidence The document is an intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying the stock exchange of a scheduled Board meeting to consider and approve audited financial results. It is an announcement to the exchange rather than the report itself and does not involve board member changes, so the appropriate category is a general regulatory announcement (Regulatory Filings).
2026-05-21 English
Dear Sir/Ma''am, Please find Intimation under Reg 30 of SEBI (LODR) Regulations, 2015 for change in name of Managing Director of the company.
Board/Management Information Classification · 90% confidence The document is an intimation under SEBI LODR Regulation 30 informing BSE and the market of a change in the name of the Managing Director. It announces a change in senior management personnel (board-level change). This aligns with the category for announcements of changes in directors or senior management (Board/Management Information).
2026-05-19 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.